CD47 and breast cancer: Increasing body of evidence shows the overexpression of CD47 in a variety of tumors, e.g., anaplastic thyroid carcinoma, esophageal squamous cell carcinoma, glioblastoma, T cell lymphoblastic leukemia, and bladder and breast cancer.